Premium
HER‐2/neu–derived peptide epitopes are also recognized by cytotoxic CD3 + CD56 + (natural killer T) lymphocytes
Author(s) -
Baxevanis Constantin N.,
Gritzapis Angelos D.,
Tsitsilonis Ourania E.,
Katsoulas Haralabos L.,
Papamichail Michael
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10251
Subject(s) - cytotoxic t cell , epitope , ctl* , biology , major histocompatibility complex , immunology , interleukin 21 , cytotoxicity , mhc class i , cd8 , antigen , cancer research , microbiology and biotechnology , in vitro , biochemistry
The human HER‐2/neu gene encodes a 185 kDa transmembrane glycoprotein recognized by MHC class I–restricted CTLs. Here, we report that HER‐2/neu peptide CTL epitopes can also be recognized by cytotoxic NK‐T lymphocytes. Unfractionated peptides derived from HLA‐A2 + , HER‐2/neu + tumor cells acid cell extract (ACE), collected from patients with metastatic ovarian cancer, were used as antigen to generate in vitro cytotoxic effectors. ACE was able to elicit from cancer patients' PBMCs both αβTCR + CD3 + CD56 − and αTCR + CD3 + CD56 + (NK‐T) CTLs that lysed ACE‐sensitized T2 cells in an HLA‐A2–restricted manner. The same CTL lines also recognized T2 cells pulsed with HER‐2/neu–derived CTL peptide epitopes, a HER‐2/neu–transfected HLA‐A2 + cell line and autologous tumor cells. αTCR + CD3 + CD56 + CTL lines also exhibited NK‐like cytotoxicity against autologous tumor cells. CTL clones were isolated from αTCR + CD3 + CD56 + bulk cultures displaying both MHC‐ and non‐MHC–restricted cytotoxicity, thus confirming the dual cytolytic function of such cells. Our data demonstrate that ACE from metastatic ovarian tumors can be used as multiepitope vaccines for generating in vitro, besides classical CTLs, NK‐T cells exerting efficient MHC‐ and non‐MHC–restricted cytotoxicity against autologous tumor targets. Such NK‐T cells expressing dual cytotoxic activity may prove advantageous in cancer immunotherapy. © 2002 Wiley‐Liss, Inc.